Literature DB >> 33438577

MITF reprograms the extracellular matrix and focal adhesion in melanoma.

Ramile Dilshat1, Valerie Fock1, Colin Kenny2, Ilse Gerritsen1, Romain Maurice Jacques Lasseur1, Jana Travnickova3, Ossia M Eichhoff4, Philipp Cerny1, Katrin Möller1, Sara Sigurbjörnsdóttir1, Kritika Kirty1, Berglind Ósk Einarsdottir1, Phil F Cheng4, Mitchell Levesque4, Robert A Cornell2, E Elizabeth Patton3, Lionel Larue5, Marie de Tayrac6,7, Erna Magnúsdóttir8, Margrét Helga Ögmundsdóttir1, Eirikur Steingrimsson1.   

Abstract

The microphthalmia-associated transcription factor (MITF) is a critical regulator of melanocyte development and differentiation. It also plays an important role in melanoma where it has been described as a molecular rheostat that, depending on activity levels, allows reversible switching between different cellular states. Here, we show that MITF directly represses the expression of genes associated with the extracellular matrix (ECM) and focal adhesion pathways in human melanoma cells as well as of regulators of epithelial-to-mesenchymal transition (EMT) such as CDH2, thus affecting cell morphology and cell-matrix interactions. Importantly, we show that these effects of MITF are reversible, as expected from the rheostat model. The number of focal adhesion points increased upon MITF knockdown, a feature observed in drug-resistant melanomas. Cells lacking MITF are similar to the cells of minimal residual disease observed in both human and zebrafish melanomas. Our results suggest that MITF plays a critical role as a repressor of gene expression and is actively involved in shaping the microenvironment of melanoma cells in a cell-autonomous manner.
© 2021, Dilshat et al.

Entities:  

Keywords:  MITF; cancer biology; extracellular matrix; focal adhesion; genetics; genomics; human; melanoma; repression

Mesh:

Substances:

Year:  2021        PMID: 33438577      PMCID: PMC7857731          DOI: 10.7554/eLife.63093

Source DB:  PubMed          Journal:  Elife        ISSN: 2050-084X            Impact factor:   8.140


  87 in total

1.  Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression.

Authors:  G Denecker; N Vandamme; O Akay; D Koludrovic; J Taminau; K Lemeire; A Gheldof; B De Craene; M Van Gele; L Brochez; G M Udupi; M Rafferty; B Balint; W M Gallagher; G Ghanem; D Huylebroeck; J Haigh; J van den Oord; L Larue; I Davidson; J-C Marine; G Berx
Journal:  Cell Death Differ       Date:  2014-04-25       Impact factor: 15.828

2.  Eos, MITF, and PU.1 recruit corepressors to osteoclast-specific genes in committed myeloid progenitors.

Authors:  Rong Hu; Sudarshana M Sharma; Agnieszka Bronisz; Ruchika Srinivasan; Uma Sankar; Michael C Ostrowski
Journal:  Mol Cell Biol       Date:  2007-04-02       Impact factor: 4.272

3.  A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma.

Authors:  Julie Caramel; Eftychios Papadogeorgakis; Louise Hill; Gareth J Browne; Geoffrey Richard; Anne Wierinckx; Gerald Saldanha; Joy Osborne; Peter Hutchinson; Gina Tse; Joël Lachuer; Alain Puisieux; J Howard Pringle; Stéphane Ansieau; Eugene Tulchinsky
Journal:  Cancer Cell       Date:  2013-09-26       Impact factor: 31.743

4.  Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells.

Authors:  Jane Goodall; Suzanne Carreira; Laurence Denat; Dominique Kobi; Irwin Davidson; Paolo Nuciforo; Richard A Sturm; Lionel Larue; Colin R Goding
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

5.  Toward Minimal Residual Disease-Directed Therapy in Melanoma.

Authors:  Florian Rambow; Aljosja Rogiers; Oskar Marin-Bejar; Sara Aibar; Julia Femel; Michael Dewaele; Panagiotis Karras; Daniel Brown; Young Hwan Chang; Maria Debiec-Rychter; Carmen Adriaens; Enrico Radaelli; Pascal Wolter; Oliver Bechter; Reinhard Dummer; Mitchell Levesque; Adriano Piris; Dennie T Frederick; Genevieve Boland; Keith T Flaherty; Joost van den Oord; Thierry Voet; Stein Aerts; Amanda W Lund; Jean-Christophe Marine
Journal:  Cell       Date:  2018-07-12       Impact factor: 41.582

6.  In vivo switching of human melanoma cells between proliferative and invasive states.

Authors:  Keith S Hoek; Ossia M Eichhoff; Natalie C Schlegel; Udo Döbbeling; Nikita Kobert; Leo Schaerer; Silvio Hemmi; Reinhard Dummer
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701

7.  A tripartite transcription factor network regulates primordial germ cell specification in mice.

Authors:  Erna Magnúsdóttir; Sabine Dietmann; Kazuhiro Murakami; Ufuk Günesdogan; Fuchou Tang; Siqin Bao; Evangelia Diamanti; Kaiqin Lao; Berthold Gottgens; M Azim Surani
Journal:  Nat Cell Biol       Date:  2013-07-14       Impact factor: 28.824

8.  Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling.

Authors:  Eishu Hirata; Maria Romina Girotti; Amaya Viros; Steven Hooper; Bradley Spencer-Dene; Michiyuki Matsuda; James Larkin; Richard Marais; Erik Sahai
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

9.  Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state.

Authors:  Mohammad Fallahi-Sichani; Verena Becker; Benjamin Izar; Gregory J Baker; Jia-Ren Lin; Sarah A Boswell; Parin Shah; Asaf Rotem; Levi A Garraway; Peter K Sorger
Journal:  Mol Syst Biol       Date:  2017-01-09       Impact factor: 11.429

10.  MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment.

Authors:  Stefanie Riesenberg; Angela Groetchen; Robert Siddaway; Tobias Bald; Julia Reinhardt; Denise Smorra; Judith Kohlmeyer; Marcel Renn; Bengt Phung; Pia Aymans; Tobias Schmidt; Veit Hornung; Irwin Davidson; Colin R Goding; Göran Jönsson; Jennifer Landsberg; Thomas Tüting; Michael Hölzel
Journal:  Nat Commun       Date:  2015-11-04       Impact factor: 14.919

View more
  19 in total

Review 1.  Signal pathways of melanoma and targeted therapy.

Authors:  Weinan Guo; Huina Wang; Chunying Li
Journal:  Signal Transduct Target Ther       Date:  2021-12-20

Review 2.  The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval.

Authors:  Mariana Matias; Jacinta O Pinho; Maria João Penetra; Gonçalo Campos; Catarina Pinto Reis; Maria Manuela Gaspar
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

3.  Fate mapping melanoma persister cells through regression and into recurrent disease in adult zebrafish.

Authors:  Jana Travnickova; Sarah Muise; Sonia Wojciechowska; Alessandro Brombin; Zhiqiang Zeng; Adelaide I J Young; Cameron Wyatt; E Elizabeth Patton
Journal:  Dis Model Mech       Date:  2022-09-16       Impact factor: 5.732

4.  SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas.

Authors:  Eliot Y Zhu; Jesse D Riordan; Marion Vanneste; Michael D Henry; Christopher S Stipp; Adam J Dupuy
Journal:  NPJ Precis Oncol       Date:  2022-10-21

5.  MITF reprograms the extracellular matrix and focal adhesion in melanoma.

Authors:  Ramile Dilshat; Valerie Fock; Colin Kenny; Ilse Gerritsen; Romain Maurice Jacques Lasseur; Jana Travnickova; Ossia M Eichhoff; Philipp Cerny; Katrin Möller; Sara Sigurbjörnsdóttir; Kritika Kirty; Berglind Ósk Einarsdottir; Phil F Cheng; Mitchell Levesque; Robert A Cornell; E Elizabeth Patton; Lionel Larue; Marie de Tayrac; Erna Magnúsdóttir; Margrét Helga Ögmundsdóttir; Eirikur Steingrimsson
Journal:  Elife       Date:  2021-01-13       Impact factor: 8.140

6.  NRF2 Enables EGFR Signaling in Melanoma Cells.

Authors:  Julia Katharina Charlotte Kreß; Christina Jessen; André Marquardt; Anita Hufnagel; Svenja Meierjohann
Journal:  Int J Mol Sci       Date:  2021-04-07       Impact factor: 5.923

Review 7.  The Impact of Hyaluronan on Tumor Progression in Cutaneous Melanoma.

Authors:  Piia Takabe; Hanna Siiskonen; Aino Rönkä; Kirsi Kainulainen; Sanna Pasonen-Seppänen
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244

Review 8.  How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance.

Authors:  Anja Wessely; Theresa Steeb; Carola Berking; Markus Vincent Heppt
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

9.  BRN2 is a non-canonical melanoma tumor-suppressor.

Authors:  Michael Hamm; Pierre Sohier; Valérie Petit; Jérémy H Raymond; Véronique Delmas; Madeleine Le Coz; Franck Gesbert; Colin Kenny; Zackie Aktary; Marie Pouteaux; Florian Rambow; Alain Sarasin; Nisamanee Charoenchon; Alfonso Bellacosa; Luis Sanchez-Del-Campo; Laura Mosteo; Martin Lauss; Dies Meijer; Eirikur Steingrimsson; Göran B Jönsson; Robert A Cornell; Irwin Davidson; Colin R Goding; Lionel Larue
Journal:  Nat Commun       Date:  2021-06-17       Impact factor: 14.919

10.  Stabilization of β-catenin promotes melanocyte specification at the expense of the Schwann cell lineage.

Authors:  Sophie Colombo; Valérie Petit; Roselyne Y Wagner; Delphine Champeval; Ichiro Yajima; Franck Gesbert; Zackie Aktary; Irwin Davidson; Véronique Delmas; Lionel Larue
Journal:  Development       Date:  2022-01-24       Impact factor: 6.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.